CYT(Delisted)
Cyteir Therapeutics·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CYT
Cyteir Therapeutics, Inc.
128 Spring St, Building A, Suite 510, Lexington, MA 02421
--
Cyteir Therapeutics, Inc., was established on June 4, 2012 as a Delaware corporation. They are a clinical-stage biotechnology company focused on developing and commercializing next-generation precision oncology drugs that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Synthetic lethality is a clinically validated method of drug development that occurs when either of the two conditions is deficient, which are tolerable in cells alone but fatal together. Their main project, CYT-0851, along with the next-generation drug candidate CYT-1853, utilizes a new function to obtain a synthetic lethal relationship, namely the relationship between the overexpression of cytidine deaminases (CDs) in the DNA damage gene family and the functional inhibition of homologous recombination (HR), a DNA repair pathway that is crucial for the survival of some cancers.
Company Financials
EPS
CYT has released its 2023 Q1 earnings. EPS was reported at -0.35, versus the expected -0.27, missing expectations. The chart below visualizes how CYT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
